Single-center retrospective series of fourteen patients with mucosal melanoma of the nasal cavity and paranasal sinuses

Eur Ann Otorhinolaryngol Head Neck Dis. 2016 Dec;133(6):387-391. doi: 10.1016/j.anorl.2016.07.003. Epub 2016 Aug 5.


Objectives: Mucosal melanoma of the nasal cavity and paranasal sinuses is a rare and highly aggressive tumor. We report our experience over 20 years in management of this tumor.

Patients and methods: A retrospective study included 14 patients with primary sinonasal mucosal melanoma.

Results: The series comprised 8 male and 6 female patients, with a median age at diagnosis of 67 years. Staging on the American Joint Committee on Cancer classification of sinus cancer was 14% T2, 22% T3, 75% T4a and 7% T4b. All patients underwent primary surgical treatment; 71% received adjuvant external radiotherapy. Median recurrence-free interval was 28.7 months. Two- and 5-year overall survival was 43% and 32%, respectively. Median follow-up was 43 months.

Conclusions: Mucosal melanomas of the nasal cavity and paranasal sinuses are very specific entities. Limited pathophysiological knowledge still precludes effective medium- and long-term management. Future treatment will probably be based on global adjuvant or neoadjuvant-targeted chemotherapy.

Keywords: Mucosal melanoma; Nasal cavity; Paranasal sinuses.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Melanoma / mortality
  • Melanoma / pathology*
  • Melanoma / therapy
  • Middle Aged
  • Nasal Cavity / pathology*
  • Nasal Cavity / surgery
  • Nasal Mucosa / pathology*
  • Nasal Mucosa / surgery
  • Neoplasm Recurrence, Local
  • Nose Neoplasms / mortality
  • Nose Neoplasms / pathology*
  • Nose Neoplasms / therapy
  • Paranasal Sinus Neoplasms / mortality
  • Paranasal Sinus Neoplasms / pathology*
  • Paranasal Sinus Neoplasms / therapy
  • Radiotherapy, Adjuvant
  • Retrospective Studies